Volume Alert - GILD 105.07 Gilead Sciences $GILD Hit a high

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 11:02 AM

Volume Alert - GILD 105.07 Gilead Sciences $GILD Hit a high today of 107.05 Closing the day 10:30 at 105.07 -1.83 -1.71% With a day low of 104.42 and a total volume of 6,541,977.

GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/

GILD Gilead Sciences Recent Headline News

Why Gilead Sciences (GILD) Isn't Done Growing Earnings Yet - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 18 mins ago
Gilead Sciences which is in the Biotechnology space, saw EPS growth of nearly 11% last year, and is looking great for this year too.
GILD: 105.07 (-1.83)

Gilead prices USD4bn senior unsecured notes in three tranches
M2 - Thu Nov 13, 6:01AM CST
Biopharmaceutical company Gilead Sciences (NasdaqGS:GILD) said on Wednesday that it has priced its USD4bn senior unsecured notes in a public offering.
GILD: 105.07 (-1.83)

Final Glance: Biotechnology companies
AP - Wed Nov 12, 5:02PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 105.09 (-1.81), AMGN: 162.01 (+0.08), CELG: 108.62 (+0.37)

Gilead Prices $4 Billion of Senior Unsecured Notes
Business Wire - Wed Nov 12, 4:59PM CST
Gilead Sciences, Inc. (NASDAQ: GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $4 billion, in an underwritten, registered public offering, consisting of three tranches:
GILD: 105.09 (-1.81)

Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 197.49 (+0.98), JNJ: 109.37 (+0.62), GILD: 105.09 (-1.81), ABBV: 64.38 (+0.62)

Gilead Sciences Falls 1.03% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Nov 12, 3:37PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.70 to a high of $107.81. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $106.33 on volume of 12.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 105.09 (-1.81)

Look for Shares of Gilead Sciences to Potentially Rebound after Yesterday's 1.03% Sell Off
Comtex SmarTrend(R) - Wed Nov 12, 3:37PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.70 to a high of $107.81. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $106.33 on volume of 12.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 105.08 (-1.82)

Gilead Sciences Gets Ambushed By The Patent Troll, AbbVie
Small Pharma Analyst - at Seeking Alpha - Wed Nov 12, 2:25PM CST

GILD: 105.08 (-1.82), ABBV: 64.38 (+0.62)

Sub-Optimal 39% Hep C Cure Rate Keeps Merck In Gilead's Rear View
Shock Exchange - at Seeking Alpha - Wed Nov 12, 2:13PM CST

GILD: 105.08 (-1.82), MRK: 59.89 (+0.58)

Should Investors Buy Twitter Following Its Analyst Day?
at The Street - Wed Nov 12, 2:08PM CST
The CNBC's 'Fast Money Halftime' trading panel says Twitter has a lot of potential but needs to find a way to grow its user base and engagement.
DHI: 24.39 (+0.38), FB: 74.60 (-0.12), WMT: 81.89 (+2.69), M: 60.96 (-0.61), BZH: 19.08 (+0.46), TLT: 118.62 (-0.01), DNKN: 48.94 (+0.85), SPY: 204.67 (+0.71), TJX: 63.71 (-0.02), EBAY: 54.46 (+0.40), QQQ: 103.22 (+0.76), GILD: 105.08 (-1.82), TGT: 67.61 (+0.89), DIA: 176.89 (+0.85), FL: 55.66 (-0.07), IWM: 117.99 (+0.09), TWTR: 42.71 (+0.17), TOL: 33.87 (+0.36), AAPL: 113.21 (+1.96)

Midday Glance: Biotechnology companies
AP - Wed Nov 12, 12:23PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
GILD: 105.08 (-1.82), AMGN: 162.01 (+0.08), CELG: 108.62 (+0.37)

Searching The Stars For Quality Stocks
Brad Kenagy - at Seeking Alpha - Wed Nov 12, 10:43AM CST

PCAR: 66.98 (+0.08), GILD: 105.08 (-1.82), AMP: 130.42 (+0.14), CMCSA: 54.45 (+0.85)

Update: These 2 Combinations Will Further Strengthen Gilead's HCV Portfolio
IAEResearch - at Seeking Alpha - Wed Nov 12, 10:17AM CST

GILD: 105.08 (-1.82)

Early Glance: Biotechnology companies
AP - Wed Nov 12, 10:05AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 105.08 (-1.82), AMGN: 162.01 (+0.08), CELG: 108.62 (+0.37)

Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 116.42 (-0.26), GILD: 105.08 (-1.82), ACHN: 14.61 (-0.24), DNDN: 0.15 (-0.01), AMGN: 162.01 (+0.08), ABBV: 64.38 (+0.62), REGN: 399.91 (-1.20)

Earnings Forecast Recap for Alibaba, Apple, Zynga, Gilead Sciences, Dendreon, and Juniper
PR Newswire - Wed Nov 12, 7:45AM CST
EarningForecast.com has issued six earnings forecast research reports with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), Apple (NASDAQ:AAPL), Zynga (NASDAQ:ZNGA), Gilead Sciences (NASDAQ:GILD), Dendreon (NASDAQ

NDN), and Juniper (NYSE:JNPR).
GILD: 105.08 (-1.82), DNDN: 0.15 (-0.01), ZNGA: 2.84 (+0.03), AAPL: 113.20 (+1.95), JNPR: 20.66 (-0.21), BABA: 118.45 (+0.25)

This Tiny Biotech Is Piggybacking on Gilead Sciences, Inc.'s Success
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 7:43AM CST
Source: Gilead Sciences. Developing drugs that help established blockbusters work better is a major trend in biotechnology. It's a lower-stakes game because drug developers only need to show that their products can improve upon existing therapies,...
GILD: 105.08 (-1.82), ACHN: 14.61 (-0.24), MRK: 59.89 (+0.58)

Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST

WDFC: 77.99 (+0.18), SJR: 26.27 (+0.07), PRGO: 155.77 (+0.90), XYL: 37.42 (-0.13), CHRW: 72.88 (+0.02), MDLZ: 38.15 (+0.23), MKC: 73.46 (+0.23), MDU: 25.21 (-0.21), SYY: 38.88 (-0.06), PDCO: 45.73 (+0.60), PNR: 68.74 (+0.30), TRI: 38.20 (-0.04), UPS: 108.52 (-0.10), PEP: 98.62 (+1.46), AGN: 197.49 (+0.98), MSI: 64.36 (+0.66), NOV: 71.49 (-1.51), NWN: 47.04 (-0.05), EGN: 66.91 (-1.79), EBAY: 54.46 (+0.40), QCOM: 70.70 (+0.41), AMAT: 22.82 (+0.33), ACN: 84.55 (+0.43), AAPL: 113.20 (+1.95), MA: 84.27 (-0.08), SCHW: 28.81 (+0.03), STR: 23.84 (-0.10), SE: 38.26 (-0.70), GAS: 51.87 (-0.25), IRM: 38.09 (+0.04), WM: 49.38 (unch), CMP: 88.80 (+0.11), VRSK: 63.04 (-0.08), GILD: 105.08 (-1.82), EXPD: 43.87 (-0.04), TFX: 114.53 (+0.06), CVS: 90.03 (+0.74), PG: 89.76 (+0.28), PX: 126.61 (+0.38), NVS: 94.38 (+1.72)

Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 197.49 (+0.98), GILD: 105.08 (-1.82), ABBV: 64.38 (+0.62), BMY: 58.03 (-0.58)

Gilead up on Harvoni results
at Investor's Business Daily - Tue Nov 11, 5:30PM CST
The drugmaker said that its new Harvoni drug achieved cure rates of 96%-97% in a study of patients who had cirrhosis and had failed to respond to prior treatments. Harvoni is Gilead's (GILD) hepatitis C pill that combines its blockbuster Sovaldi drug...
GILD: 105.08 (-1.82)

Gilead Sciences Inc. (GILD) Stock Research Links

GILD Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Divorce Expertise: Obenhaus Adds CDFA Credential

Divorce isn't just a legal tangled mess; it's a financial minefield as well. Lindsey Obenhaus from Goranson Bain Ausley has beefed up her credentials with a Certified Divorce Financial Analyst® (CDFA®) designation, lending a sharper edge to her approach in divorce financials. When relationships turn sour, so do wallets, and Obenhaus aims to soften that blow for her...

Motor Sensor Market to Exceed $5B by 2035 Surge

Motor Sensor Market: Facing a New Era of Growth Buckle up, because this motor sensor market is gearing up for one heck of a ride. We're talking a clunky, gritty transition where the market's supposed to rev up to $5.47 billion by 2035, shooting from $3.21 billion in 2026. If you are crunching those numbers like a true market dog, that's a decent CAGR of 6.1%. But what's...

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Gemmy's Orchestra of Lights Op. 2 Unveils New Show

Jazzing Up the Holidays with Gemmy's Latest Innovation Just when you thought holiday displays couldn't get more extravagant, along comes Gemmy with its latest wonder—the Orchestra of Lights™ Op. 2. Exclusively hitting Lowe's shelves, this isn't your average set of twinkling bulbs. It's an all-out sensory assault, mixing tunes straight out of yuletide hit lists with...

COhatch Preps for High-Stakes Ohio Pitch Contest

Ohio Startups Gear Up for Another Fierce Faceoff You wouldn't find me betting against a hungry entrepreneur, especially with $25,000 on the line. That's the prize dangling at this year's Dublin Pitch Competition, hosted by COhatch and the City of Dublin. If there's one thing I'm certain of, it's that Ohio will see some real contenders stepping up on October 15....

Chemours Faces Class Action Over Fraud Allegations

Chemours and the Aftermarket Mirage When it rains, it pours, and for Chemours, the forecast isn't looking sunny. Investors are gearing up to slap Chemours Company (NYSE: CC) with a securities fraud class action. Why, you ask? Overstatement of aftermarket demand for refrigerants left investors high and dry after stock prices took an 18% nosedive. On August 4, 2026,...

WellBe Taps New Tech Chief to Elevate Home Care

In a move that's got the healthcare world buzzing, WellBe Senior Medical just brought in a heavyweight to steer its digital ship. They've appointed Jeffrey Brown as their new Chief Digital & Information Officer. What's shaking? Brown's stepping into the ring to tackle the age-old healthcare dilemma: making tech work smarter, not harder, especially at home. From High-Tech...

Stephen A. Smith Calls for Corporate Support of HBCUs

A Stand for Education at the White House Stephen A. Smith stirred the pot with his decision to attend a White House dinner, a move that had tongues wagging across the media landscape. But this time, it wasn't about the usual hustle and bustle of the sports world. Smith had his sights set on the big picture, specifically, the long-term financial stability of Historically...

Lowcountry Kids to Get Free Helmets at Safety Events

Helmets for Kids Initiative Gets Rolling Now, here's a story that's more about community care than cash flow, but hey, sometimes even a grizzled trader like me can nod in appreciation. Christmas Injury Lawyers are putting their money where their mouth is, with the Helmets for Kids initiative staged at two key events in the Lowcountry area. Yep, that's right—the legal...

Reel Drops: Eightpoint's New Social Drama App Explored

Mobile Drama: A Quick Escape with Reel Drops In this fast-moving world, where time feels as elusive as a daydream, Eightpoint is shaking up mobile entertainment with its brand-new app, Reel Drops. Based out of George Town, Cayman Islands, this app aims to give viewers a shot at swift, captivating storytelling without the marathon commitment of a binge-watch session. A New...